- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02738684
A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test
April 13, 2016 updated by: XIAOTIANDAI, Southwest Hospital, China
A Small Sample Exploratory Study to Predict Gefitinib' s Efficacy for Late Stage Lung Adenocarcinoma Patients by Plasma Free Nucleic Acids EGFR Gene Mutation Test
This project aims to do a small sample exploratory study, to predict EGFR-TKI targeted therapy gefitinib' s efficacy in late stage lung adenocarcinoma patients (phase IIIB or IV), who have negative tissue EGFR gene mutation, positive plasma free nucleic acid EGFR gene.
Study Overview
Status
Unknown
Conditions
Detailed Description
Results of the study will clarify that if the circulating tumor DNA (ctDNA) EGFR mutation could be used as a screening method for EGFR-TKI targeted therapy for late stage lung cancer patients, as well as a standard for the therapy efficacy.
This study can be used as a standard to assess gefitinib' s efficacy after 8 weeks of treatment in IIIB or stage IV lung cancer through tumor tissue negative, ctDNA positive EGFR mutation.
Study Type
Observational
Enrollment (Anticipated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Participants in this research must meet the following criteria: histologic diagnosed of lung adenocarcinoma.
Late stage (stage IIIB or IV) lung adenocarcinoma according to the International Union against cancer (UICC) the latest version of standard cancer TNM staging.
Description
Inclusion Criteria:
- Participants in this research must meet the following criteria: histologic diagnosed of lung adenocarcinoma.
- Late stage (stage IIIB or IV) lung adenocarcinoma according to the International Union against cancer (UICC) the latest version of standard cancer TNM staging.
- tumor tissue EGFR mutation negative, and ctDNA EGFR mutation positive correlated with EGFR TKI sensitivity.
- Participants should have signed and dated on the official informed consent.
- Not less than 18 years old.
- At least 1 lesion can be exactly measured.
- Patients whose plasma free nucleic acids EGFR mutation test were positive, and willing to use gefitinib for therapy by their own expense.
Exclusion criteria:
- Patients already received EGFR-TKI treatment previously.
- Patients have pressure on the spinal cord or brain metastases, no symptom, conditions stabled, do not need to use steroid medications for 4 weeks before the start of the study.
- Patients with clinical evidence of any symptoms of severe or uncontrolled hypertension, for example, researchers believe that patients with uncontrolled hypertension and active bleeding will affect the study reliability.
- Patients with uncontrolled nausea or vomiting, chronic gastrointestinal disease, unable to swallow drugs or underwent major bowel resection may affect the full absorption of gefitinib.
- Patients meet any one of the following heart standard: in static State, 3 times ECG check shows average correction QT period (QTc) >470 msec; clinical abnormal symptom of rhythm, conduction, and static ECG, for example completely left beam conduction block, III degrees conduction block, II degrees conduction block, PR period >250 msec, various factors with risks of extended QTc or rhythm disorders, for example, congestive heart failure, low potassium blood syndrome, congenital long QT Syndrome, direct relatives has long QT syndrome or sudden unexplained death in less than 40 years old, drug combination that may prolong the QT interval.
- Patients Have the following history: ILD, drug-induced ILD, radiation Pneumonitis require steroid treatment, clinically active interstitial lung disease.
- Abnormal marrow reservation or organ function.
- Women who are breastfeeding.
- Fertile male or female, who did not taken effective contraceptive measures, women have been pregnant or breast feeding, or positive pregnancy test prior to study (urine or serum).
- Patients don't agree with the study processes, constraints and requirements, and were evaluated by researchers that can't participate in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
lung cancer
A small sample exploratory study to predict gefitinib' s efficacy for late stage lung adenocarcinoma patients by plasma free nucleic acids EGFR gene mutation test
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
RECIST 1.1 Efficacy assessments
Time Frame: 8 weeks
|
Categorisation of objective tumour response assessment at each visit will be based on the RECIST 1.1 criteria of response: CR, PR, SD and PD.
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: DAI X T, doctor, Department of Respiratory Diseases, Souty West Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2016
Primary Completion (Anticipated)
January 1, 2018
Study Completion (Anticipated)
January 1, 2018
Study Registration Dates
First Submitted
March 22, 2016
First Submitted That Met QC Criteria
April 13, 2016
First Posted (Estimate)
April 14, 2016
Study Record Updates
Last Update Posted (Estimate)
April 14, 2016
Last Update Submitted That Met QC Criteria
April 13, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- pfnaegmt-023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Adenocarcinoma
-
Hunan Cancer HospitalSuzhou Sheng Diya Biomedical Co., Ltd.Active, not recruitingAdenocarcinoma of the LungChina
-
Shanghai Pulmonary Hospital, Shanghai, ChinaRecruitingEGFR Gene Mutation | Lung Adenocarcinoma Stage III | Lung Adenocarcinoma Stage IVChina
-
Meir Medical CenterUnknownAdenocarcinoma, Bronchiolo-Alveolar | Adenocarcinoma of the LungIsrael
-
Rambam Health Care CampusUnknownLung Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Breast Adenocarcinoma
-
Intergroupe Francophone de Cancerologie ThoraciqueAstraZenecaCompletedPneumonic-type Adenocarcinoma (P-ADC) | Lung Adenocarcinoma With Bronchiolo-alveolar FeatureFrance
-
Memorial Sloan Kettering Cancer CenterCompletedOligometastatic Lung AdenocarcinomaUnited States
-
Chinese PLA General HospitalUnknown
-
Zhou ChengzhiCompletedLung Adenocarcinoma Stage IVChina
-
Simcere Pharmaceutical Co., LtdUnknownAdvanced Primary Lung AdenocarcinomaChina
-
Henan University of Traditional Chinese MedicineRecruitingEarly Stage Lung AdenocarcinomaChina